Floatz Rating
CC46/100
Confidence
Indicative
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
35Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07476027CT.gov Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL | — | Not Yet Recruiting | — | — | — |
NCT04934774CT.gov Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances | — | Unknown | — | — | — |
NCT04004637CT.gov CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · T-Lymphoblastic Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| cd19-ucart (this asset) | Institute of Hematology & Blood Diseases Hospital, China | P1 | CC · 46 |
| Vincristine Sulfate | Children's Oncology Group | P3 | BB |
| Pegaspargase | Children's Oncology Group | P3 | BB |
| Asparaginase | University of Washington | P3 | BB |
| Dexasone | Children's Oncology Group | P3 | BB |
| Cyclophosphamide | Children's Oncology Group | P3 | BB |
| Methotrexate | Children's Oncology Group | P3 | BB |
| Mercaptopurine Anhydrous | Children's Oncology Group | P3 | BB |
| Thioguanine Anhydrous | Children's Oncology Group | P3 | BB |
+42 more in the T-Lymphoblastic Lymphoma cohort
Other indications for cd19-ucart
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Non-Hodgkin Lymphoma | — | P4 | BB · 71 |
| B-Cell Acute Lymphoblastic Leukemia | — | P2 | BB · 64 |
| Acute Lymphoblastic Leukemia | — | P2 | B · 63 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. cd19-ucart in T-Lymphoblastic Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cd19-ucart-t-lymphoblastic-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →